What is Lifesci Capital’s Estimate for GLUE FY2024 Earnings?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) – Stock analysts at Lifesci Capital issued their FY2024 EPS estimates for Monte Rosa Therapeutics in a research note issued to investors on Wednesday, March 12th. Lifesci Capital analyst O. Mccammon forecasts that the company will post earnings of ($2.00) per share for the year. Lifesci Capital has a “Outperform” rating and a $19.00 price objective on the stock. The consensus estimate for Monte Rosa Therapeutics’ current full-year earnings is ($1.49) per share. Lifesci Capital also issued estimates for Monte Rosa Therapeutics’ Q4 2024 earnings at ($0.66) EPS.

Separately, Wells Fargo & Company cut Monte Rosa Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $14.00 to $11.00 in a research report on Thursday, December 19th.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE stock opened at $6.27 on Friday. Monte Rosa Therapeutics has a one year low of $3.21 and a one year high of $12.40. The firm has a market cap of $385.21 million, a P/E ratio of -3.43 and a beta of 1.50. The firm’s 50 day moving average price is $6.14 and its 200-day moving average price is $6.76.

Institutional Trading of Monte Rosa Therapeutics

Several large investors have recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new stake in Monte Rosa Therapeutics in the fourth quarter valued at about $220,000. Two Sigma Advisers LP acquired a new stake in Monte Rosa Therapeutics in the fourth quarter valued at about $180,000. Two Sigma Investments LP boosted its stake in Monte Rosa Therapeutics by 1,965.1% in the fourth quarter. Two Sigma Investments LP now owns 278,785 shares of the company’s stock valued at $1,935,000 after buying an additional 265,285 shares in the last quarter. Rafferty Asset Management LLC acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at about $192,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at about $101,000. 79.96% of the stock is owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.